TGF-β signaling was shown to be significantly increased based on detection of the phosphorylation of Smad2 and Smad3 in vivo and ex vivo when the cancer cells gained the mesenchymal phenotype after paclitaxel treatment (Figure 2) [136]. The gene discussed is TGFB1; the disease is cancer.